


## PHARMACEUTICAL 2019



## Spero Therapeutics Inc. Rank 59 of 363





## PHARMACEUTICAL 2019



## Spero Therapeutics Inc. Rank 59 of 363



The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Spero Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 185% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	124,219
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,318
Liabilities, Non-Current	0
Other Assets	1,894
Other Compr. Net Income	-28
Other Expenses	0
Other Liabilities	833
Other Net Income	1,144
Other Revenues	3,966
Property and Equipment	2,893
Research and Development	33,885
Selling, General and Administrative Expense	12,887

Output Variable	Value in 1000 USD
Assets	129,006
Liabilities	13,151
Expenses	46,772
Revenues	3,966
Stockholders Equity	115,855
Net Income	-41,662
Comprehensive Net Income	-41,676
Economic Capital Ratio	222%

